A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism
- PMID: 21718719
- DOI: 10.1016/j.neubiorev.2011.06.006
A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism
Abstract
Deficits in social approach behavior, rough-and-tumble play, and speech abnormalities are core features of autism that can be modeled in laboratory rats. Human twin studies show that autism has a strong genetic component, and a recent review has identified 99 genes that are dysregulated in human autism. Bioinformatic analysis of these 99 genes identified the NMDA receptor complex as a significant interaction hub based on protein-protein interactions. The NMDA receptor glycine site partial agonist d-cycloserine has been shown to treat the core symptom of social withdrawal in autistic children. Here, we show that rats selectively bred for low rates of play-induced pro-social ultrasonic vocalizations (USVs) can be used to model certain core symptoms of autism. Low-line animals engage in less social contact time with conspecifics, show lower rates of play induced pro-social USVs, and show an increased proportion of non-frequency modulated (i.e. monotonous) ultrasonic vocalizations, compared to non-selectively bred random-line animals. Gene expression patterns in the low-line animals show significant enrichment in autism-associated genes and the NMDA receptor family was identified as a significant hub. Treatment of low-line animals with the NMDAR glycine site partial agonist GLYX-13 rescued the deficits in play-induced pro-social 50-kHz and reduced monotonous USVs. Thus, the NMDA receptor has been shown to play a functional role in autism, and GLYX-13 shows promise for the treatment of autism. We dedicate this paper to Ole Ivar Lovaas (May 8, 1927-August 2, 2010), a pioneer in the field of autism.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Glix 13, a new drug acting on glutamatergic pathways in children and animal models of autism spectrum disorders.Biomed Res Int. 2014;2014:234295. doi: 10.1155/2014/234295. Epub 2014 Jan 30. Biomed Res Int. 2014. PMID: 24605324 Free PMC article. Review.
-
Rats selectively bred for low levels of play-induced 50 kHz vocalizations as a model for autism spectrum disorders: a role for NMDA receptors.Behav Brain Res. 2013 Aug 15;251:18-24. doi: 10.1016/j.bbr.2013.04.022. Epub 2013 Apr 23. Behav Brain Res. 2013. PMID: 23623884 Free PMC article. Review.
-
L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective.Br J Pharmacol. 1998 Aug;124(8):1767-73. doi: 10.1038/sj.bjp.0702010. Br J Pharmacol. 1998. PMID: 9756395 Free PMC article.
-
GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator.Neuropharmacology. 2005 Dec;49(7):1077-87. doi: 10.1016/j.neuropharm.2005.06.006. Epub 2005 Jul 26. Neuropharmacology. 2005. PMID: 16051282
-
Selective breeding for 50 kHz ultrasonic vocalization emission produces alterations in the ontogeny and regulation of rough-and-tumble play.Behav Brain Res. 2012 Apr 1;229(1):138-44. doi: 10.1016/j.bbr.2012.01.012. Epub 2012 Jan 13. Behav Brain Res. 2012. PMID: 22266925
Cited by
-
Dendritic structural plasticity and neuropsychiatric disease.Nat Rev Neurosci. 2018 Mar 16;19(4):215-234. doi: 10.1038/nrn.2018.16. Nat Rev Neurosci. 2018. PMID: 29545546 Free PMC article. Review.
-
Glix 13, a new drug acting on glutamatergic pathways in children and animal models of autism spectrum disorders.Biomed Res Int. 2014;2014:234295. doi: 10.1155/2014/234295. Epub 2014 Jan 30. Biomed Res Int. 2014. PMID: 24605324 Free PMC article. Review.
-
Affective preclinical modeling of psychiatric disorders: taking imbalanced primal emotional feelings of animals seriously in our search for novel antidepressants.Dialogues Clin Neurosci. 2015 Dec;17(4):363-79. doi: 10.31887/DCNS.2015.17.4/jpanksepp. Dialogues Clin Neurosci. 2015. PMID: 26869838 Free PMC article. Review.
-
Scale-Up Synthesis and Identification of GLYX-13, a NMDAR Glycine-Site Partial Agonist for the Treatment of Major Depressive Disorder.Molecules. 2018 Apr 24;23(5):996. doi: 10.3390/molecules23050996. Molecules. 2018. PMID: 29695090 Free PMC article.
-
D-Cycloserine ameliorates social alterations that result from prenatal exposure to valproic acid.Brain Res Bull. 2014 Sep;108:1-9. doi: 10.1016/j.brainresbull.2014.08.001. Epub 2014 Aug 15. Brain Res Bull. 2014. PMID: 25130667 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources